The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases.

ABSTRACT: Recently our study identified EP3 receptor and galectin-3 as prognosticators of cervical cancer. The aim of the present study was the analysis of EP2 as a novel marker and its association to EP3, galectin-3, clinical pathological parameters and the overall survival rate of cervical cancer patients. Cervical cancer tissues (n = 250), as also used in our previous study, were stained with anti-EP2 antibodies employing a standardized immunohistochemistry protocol. Staining results were analyzed by the IRS scores and evaluated for its association with clinical-pathological parameters. H-test of EP2 percent-score showed significantly different expression in FIGO I-IV stages and tumor stages. Kaplan-Meier survival analyses indicated that EP3-negative/EP2-high staining patients (EP2 IRS score ≥2)

SUBMITTER: Dietlmeier S 

PROVIDER: S-EPMC6981231 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature